TARO-DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Valsts: Kanāda
Valoda: angļu
Klimata pārmaiņas: Health Canada
Produkta apraksts
(SPC)
19-10-2022
Daži šī produkta dokumenti pašlaik nav pieejami. Varat nosūtīt pieprasījumu mūsu klientu apkalpošanas dienestam, un mēs jums paziņosim, tiklīdz mēs tos varēsim iegūt.
Nosūtīt pieprasījumu.
Nosūtīt pieprasījumu.
Aktīvā sastāvdaļa:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE)
Pieejams no:
TARO PHARMACEUTICALS INC
ATĶ kods:
N06AX23
SNN (starptautisko nepatentēto nosaukumu):
DESVENLAFAXINE
Deva:
100MG
Zāļu forma:
TABLET (EXTENDED-RELEASE)
Kompozīcija:
DESVENLAFAXINE (DESVENLAFAXINE SUCCINATE) 100MG
Ievadīšanas:
ORAL
Vienības iepakojumā:
15G/50G
Receptes veids:
Prescription
Produktu pārskats:
Active ingredient group (AIG) number: 0152509002; AHFS:
Autorizācija statuss:
APPROVED
Autorizācija datums:
2022-10-20
Produkta apraksts
PRODUCT MONOGRAPH
PR TARO-DESVENLAFAXINE
desvenlafaxine extended-release tablets
50 mg and 100 mg desvenlafaxine (as desvenlafaxine succinate
monohydrate
)
Antidepressant
Taro Pharmaceuticals Inc.
Date of Revision:
130 East Drive
OCT 19, 2022
Brampton, Ontario
L6T 1C1
Submission Control No.: 264187
_________________________________________________________________________________________
_Taro-Desvenlafaxine (desvenlafaxine succinate monohydrate) Product
Monograph _
_Page 2 of 52_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFOR
M
ATION
.............................................................................
3
SUMMARY PRODUCT INFORMATION
...................................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................................
3
CONTRAINDICATIONS
..............................................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................................
4
ADVERSE REACTIONS
............................................................................................................................11
DRUG INTERACTIONS
.............................................................................................................................21
DOSAGE AND ADMINISTRATION
.........................................................................................................24
OVERDOSAGE
...........................................................................................................................................27
ACTION AND CLINICAL PHARMACOLOGY
.......................................................................................28
STORAGE AND STABILITY
....................................................................................................................31
SPECIAL HANDLING INSTRUCTIONS
.
Izlasiet visu dokumentu
